Zydus subsidiary receives USFDA nod to market Tamiflu drug

Drug firm Zydus Cadila's US subsidiary has received approval from the US health regulator to market oseltamivir phosphate capsules used for the treatment of Tamiflu.

"Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the United States Food and Drug Administration (USFDA) to market oseltamivir phosphate capsules in strengths of 30 mg, 45 mg, and 75 mg," Cadila Healthcare said in a BSE filing.

Quoting IMS December 2016 sales data, the company said oseltamivir phosphate capsules had sales worth $382 million.

The group also received approval for antibiotic Linezolid tablets in the strength of 600 mg.

The group now has more than 110 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process in the 2003-04 financial year, it added.

Shares of Cadila Healthcare were trading 1.62 per cent higher at Rs 437 apiece on BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel